Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-04-29

FDA Approved: BRIELLYN — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)

View source ↗

Summary

FDA approved a supplemental application for BRIELLYN, a generic combined oral contraceptive containing norethindrone and ethinyl estradiol, developed by Glenmar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BRIELLYN (NORETHINDRONE AND ETHINYL ESTRADIOL)

Snippet

SUPPL AP for BRIELLYN (NORETHINDRONE AND ETHINYL ESTRADIOL)